Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3

2(28.6%)

Phase 2

2(28.6%)

N/A

2(28.6%)

Phase 4

1(14.3%)

7Total

Phase 3(2)

Phase 2(2)

N/A(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT01885390Phase 3Completed

Registry to Evaluate the ROX COUPLER in Patients With Resistant or Uncontrolled Hypertension

Role: lead

NCT02895386Not ApplicableTerminated

A Multicenter Study to Evaluate the ROX Coupler in Subjects With Hypertension

Role: lead

NCT01642498Phase 3Completed

A Multicenter Study to Evaluate the ROX Arteriovenous Coupler in Patients With Treatment-Resistant Hypertension

Role: lead

NCT01682057Phase 2Completed

A Multicenter Study to Evaluate the ROX Anastomotic Coupler System (ACS) In Patients With Severe Hypertension

Role: lead

NCT00832611Phase 4Completed

Study of the Effect of the ROX AC1 on Exercise Capacity and Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients

Role: lead

NCT00992680Phase 2Completed

A Pilot Study to Evaluate the ROX Anastomotic Coupler System in Patients With Chronic Obstructive Pulmonary Disease

Role: lead

NCT00886639Not ApplicableCompleted

Effect of Oxygen-supply on 6-Minute-Walking-Distance of COPD III/IV-patients

Role: collaborator

All 7 trials loaded